Document Detail

Effects of Aloe vera Supplementation in Subjects with Prediabetes/Metabolic Syndrome.
MedLine Citation:
PMID:  23035844     Owner:  NLM     Status:  Publisher    
Abstract Background: Metabolic syndrome affects 1 in 3 U.S. adults. The primary target of treatment of patients with metabolic syndrome is therapeutic lifestyle change. Numerous animal trials have reported positive effects of Aloe vera in in vivo models of diabetes, but there is a paucity of controlled clinical trials in patients with prediabetes. Thus, the objective of this pilot study was to examine the effect of aloe compared to placebo on fasting blood glucose, lipid profile, and oxidative stress in subjects with prediabetes/metabolic syndrome. Methods: This was a double-blind, placebo-controlled Institutional Review Board (IRB)-approved pilot study of two aloe products (UP780 and AC952) in patients with prediabetes over an 8-week period. A total of 45 subjects with impaired fasting glucose or impaired glucose tolerance and having two other features of metabolic syndrome were recruited (n=15/group). Parameters of glycemia [fasting glucose, insulin, homeostasis model assessment (HOMA), glycosylated hemoglobin (HbA1c), fructosamine, and oral glucose tolerance test (OGTT)] and oxidative stress (urinary F2-isoprostanes) were measured along with lipid profile and high-sensitivity C-reactive protein (hsCRP) levels before and after supplementation. Results: There were no significant baseline differences between groups. Compared to placebo, only the AC952 Aloe vera inner leaf gel powder resulted in significant reduction in total and low-density lipoprotein cholesterol (LDL-C) levels, glucose, and fructosamine. In the UP780 Aloe vera inner leaf gel powder standardized with 2% aloesin group, there were significant reductions in HbA1c, fructosamine, fasting glucose, insulin, and HOMA. Only the UP780 aloe group had a significant reduction in the F2-isoprostanes compared to placebo. Conclusions: Standardized aloe preparations offer an attractive adjunctive strategy to revert the impaired fasting glucose and impaired glucose tolerance observed in conditions of prediabetes/metabolic syndrome.
Sridevi Devaraj; Mesfin Yimam; Lidia A Brownell; Ishwarlal Jialal; Sital Singh; Qi Jia
Related Documents :
15953434 - Central visual function and the nei-vfq-25 near and distance activities subscale scores...
25474544 - Curcumin improves high glucose-induced ins-1 cell insulin resistance via activation of ...
21554904 - Cardioprotection by ischemic postconditioning is lost in isolated perfused heart from d...
11518504 - Elevated tgfbeta signaling inhibits ocular vascular development.
24606904 - Rbp4 activates antigen-presenting cells, leading to adipose tissue inflammation and sys...
7654714 - A spectroscopic investigation of the conformational dynamics of insulin in solution.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-4
Journal Detail:
Title:  Metabolic syndrome and related disorders     Volume:  -     ISSN:  1557-8518     ISO Abbreviation:  Metab Syndr Relat Disord     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101150318     Medline TA:  Metab Syndr Relat Disord     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
1 Department of Pathology and Immunology, Baylor College of Medicine , and Texas Children's Hospital, Houston, Texas.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pathogenesis of and strategies for preventing Edwardsiella tarda infection in fish.
Next Document:  Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.